Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation

Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation

Aim. To assess the economic efficacy of a fixed combination tiotropium bromide+olodaterol (T+O) in comparison with other medications, included in the Vital and Essential Drugs List (VEDL), for the maintenance triple therapy of chronic obstructive pulmonary disease (COPD).Materials and Methods. A Mar...

Full description

Bibliographic Details
Main Authors:	S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2020-08-01
Series:	Фармакоэкономика
Subjects:	chronic obstructive pulmonary disease maintenance therapy bronchodilators tiotropium olodaterol fixed combination cost-minimization analysis budget impact analysis cost-effectiveness analysis pharmacoeconomic modeling
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/383

Similar Items

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD
by: Tebboth A, et al.
Published: (2016-11-01)

Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis
by: Marc Miravitlles, et al.
Published: (2017-11-01)

Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study
by: Kawachi S, et al.
Published: (2019-05-01)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
by: Tamura T, et al.
Published: (2016-11-01)

Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results
by: Hoogendoorn M, et al.
Published: (2019-02-01)

Prevention of copd exacerbations. Focus on dual bronchodilators
by: V. V. Arkhipov
Published: (2018-10-01)

COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD
by: E. G. Kosolapov, et al.
Published: (2017-08-01)

Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score–matched cohort analysis
by: Shigeo Muro, et al.
Published: (2021-06-01)

Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies
by: LaForce C, et al.
Published: (2018-06-01)

Tiotropium in COPD: clinical outcomes and economic evidence
by: Orietta Zaniolo, et al.
Published: (2010-03-01)

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)
by: Beeh KM, et al.
Published: (2016-02-01)

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study
by: Sauer R, et al.
Published: (2016-04-01)

Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients
by: Valipour A, et al.
Published: (2019-10-01)

No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD
by: Andreas S, et al.
Published: (2020-08-01)

Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting
by: Steinmetz KO, et al.
Published: (2019-07-01)

TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow
by: Mahler DA, et al.
Published: (2021-08-01)

Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study
by: Valipour A, et al.
Published: (2021-03-01)

Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD
by: Andreas S, et al.
Published: (2020-08-01)

Effects of baseline symptom burden on treatment response in COPD
by: Martinez FJ, et al.
Published: (2019-01-01)

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol
by: Buhl R, et al.
Published: (2020-10-01)

Tiotropium/Olodaterol treatment reduces cigarette smoke extract-induced cell death in BEAS-2B bronchial epithelial cells
by: Cheng-hsiung Chen, et al.
Published: (2020-10-01)

Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients
by: Miravitlles M, et al.
Published: (2016-01-01)

Tiotropium: a new therapeutic option in asthma
by: F. Novelli, et al.
Published: (2013-12-01)

Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropiumolodaterol in patients with chronic obstructive pulmonary disease
by: S. K. Zyryanov, et al.
Published: (2018-04-01)

Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Cost-effectiveness analysis of tiotropium bromide and salmeterol in the treatment of severe chronic opstructive pulmonary disease
by: Stojanović Stefan
Published: (2012-01-01)

Pharmacoeconomic aspects of the use of bronchodilators in the management of COPD: real clinical practice
by: Р. A. Balunov, et al.
Published: (2019-01-01)

Pharmacoeconomic analysis of the anidulafungin (EraxisR) in adult patients with invasive candidiasis
by: S. V. Nedogoda, et al.
Published: (2019-10-01)

EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS
by: M. Yu. Frolov, et al.
Published: (2017-05-01)

Pharmacoeconomic analysis of subdermal tocilizumab in patients with rheumatoid arthritis
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Tiotropium as essential maintenance therapy in COPD
by: M. Decramer
Published: (2006-12-01)

The efficacy and safety of combined tiotropium and olodaterol via the Respimat® inhaler in patients with COPD: results from the Japanese sub-population of the Tonado® studies
by: Ichinose M, et al.
Published: (2016-08-01)

Striving for optimal bronchodilation: focus on olodaterol
by: Incorvaia C, et al.
Published: (2016-03-01)

Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria
by: S. V. Nedogoda, et al.
Published: (2019-07-01)

Pharmacoeconomic analysis of perampanel for resistance partial epilepsy
by: D. Yu. Belousov, et al.
Published: (2018-06-01)

PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
by: A. U. Kulikov, et al.
Published: (2015-03-01)

Experience of using double bronchodilation therapy in patients with COPD
by: I. V. Demko, et al.
Published: (2021-01-01)

Pharmacoeconomic aspects of using enzalutamide for treatment of patients with nonmetastatic castration-resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2020-07-01)

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
by: N. A. Avksentyev, et al.
Published: (2018-08-01)

COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD
by: E. G. Kosolapov, et al.
Published: (2017-08-01)